journal article·2026-02Open access

Genetically programmable protein-biomineral core-shell nanovectors for enhancing tumor microenvironment-activated chemotherapy

Kaiyue Zhang, Xincheng Sun, Ting Ji, Xinchen Shen, Yao Li, Hang Zhao, Xinyi Yang, Hu Li, Wenwen Huang

Abstract

Limited chemotherapy efficacy results in frequent treatment failure events in multiple malignant tumors. Because of limited aqueous solubility, short retention time in the tumor, lack of selectivity toward cancerous cells and non-specific toxicity, there is urgent demand for the discovery of innovative cancer drugs with improved efficacy and selectivity. While nanotechnology offers promising solutions for drug delivery, many nanocarriers still face challenges such as premature drug leakage during circulation, insufficient tumor-specific accumulation, and potential off-target toxicity. To address these limitations, we utilize genetically engineered silk-elastin-like proteins (SELPs) as potent tumor-responsive drug carriers. Tumor cells α v β 3 receptor-specific internalizing RGD peptide (iRGD) was encoded into amphiphilic SELP sequences (S2E3i4Y) to form cancer-selective nanoparticles. To minimize the nonspecific uptake and reduce the leakage of loaded doxorubicin (DOX) during blood circulation, calcium phosphate (CaP) shells were fabricated to be the encapsulation layer of the S2E3i4Y-DOX nanoparticles (S2E3i4Y@CaP-DOX), which prevented premature drug leakage, enhanced the therapeutic safety, and minimized toxicity associated with nonspecific delivery. Meanwhile, the acidic-sensitive CaP shells can be decomposed specifically at the tumor sites, initiating the inner S2E3i4Y-DOX couple to α v β 3 -expressing cancer cells for improved tumor-targeting and prolonged tumor retention. In vivo assays revealed that S2E3i4Y@CaP-DOX successfully achieved an impressive 4T1 tumor inhibition rate of 75.9%, much higher than free DOX, without side effects. This core-shell SELP-based platform provides a biocompatible, efficient, and sustainable nanoplatform for tumor-responsive drug delivery, offering a promising strategy for enhanced cancer therapy with spatiotemporal precision.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Silk-based biomaterials and applications · Connective tissue disorders research · Advanced Materials and Mechanics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (57)

Show source-provided references
1. Breast cancer: pathogenesis and treatments10.1038/s41392-024-02108-4 ↗
2. Rational cancer treatment combinations: an urgent clinical need10.1016/j.molcel.2020.05.031 ↗
3. Timeline: chemotherapy and the war on cancer10.1038/nrc1529 ↗
4. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer10.1056/NEJMoa055531 ↗
5. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer10.1056/NEJM199812313392704 ↗
6. Combined chemotherapy and radiotherapy for locally advanced breast cancer10.1016/0014-2964(80)90352-7 ↗
7. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus10.1056/NEJM199206113262403 ↗
8. Optimization of combined chemoradiotherapy and immunotherapy for locally advanced esophageal cancer
9. Immunogenic bifunctional nanoparticle suppresses programmed cell death-ligand 1 in cancer and dendritic cells to enhance adaptive immunity and chemo-immunotherapy10.1021/acsnano.3c12678 ↗
10. Neoadjuvant chemotherapy by liposomal doxorubicin boosts immune protection of tumor membrane antigens-based nanovaccine
11. Residual ANTXR1+ myofibroblasts after chemotherapy inhibit anti-tumor immunity via YAP1 signaling pathway10.1038/s41467-024-45595-3 ↗
12. Outer membrane vesicle-wrapped manganese nanoreactor for augmenting cancer metalloimmunotherapy through hypoxia attenuation and immune stimulation10.1016/j.actbio.2024.05.010 ↗
13. Targeted inhibition of lymphovascular invasion formation with CREKA peptide-modified silicasomes to boost chemotherapy in bladder cancer10.1021/acs.nanolett.4c02485 ↗
14. Adaptive design of nanovesicles overcoming immunotherapeutic limitations of chemotherapeutic drugs through poliovirus receptor blockade10.1021/acsnano.3c13056 ↗
15. Recent progress of supramolecular chemotherapy based on host-guest interactions
16. Nanoparticle and targeted systems for cancer therapy10.1016/j.addr.2004.02.014 ↗
17. Tumor penetrating peptides for improved drug delivery10.1016/j.addr.2016.03.008 ↗
18. New perspectives in cell adhesion: RGD and integrins10.1126/science.2821619 ↗
19. Glycoengineering-based anti-PD-1-iRGD peptide conjugate boosts antitumor efficacy through T cell engagement
20. A triple-mode strategy on JQ1-loaded nanoplatform for superior antitumor therapy in pancreatic cancer
21. Multienzyme-like reactivity cooperatively impairs glutathione peroxidase 4 and ferroptosis suppressor protein 1 pathways in triple-negative breast cancer for sensitized ferroptosis therapy10.1021/acsnano.1c08664 ↗
22. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates10.1016/j.biomaterials.2014.06.042 ↗
23. Self-assembly of peptide dendrimers and their bio-applications in theranostics
24. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs10.1126/science.1183057 ↗
25. Activatable iRGD-based peptide monolith: targeting, internalization, and fluorescence activation for precise tumor imaging10.1016/j.jconrel.2016.06.032 ↗
26. Enhancing tumor targeted therapy: the role of iRGD peptide in advanced drug delivery systems10.3390/cancers16223768 ↗
27. Silk protein-based nanoporous microsphere for controllable drug delivery through self-assembly in ionic liquid system10.1021/acs.biomac.3c01104 ↗
28. Tumor microenvironment as a therapeutic target in cancer10.1016/j.pharmthera.2020.107753 ↗
29. Targeting ROS in cancer: rationale and strategies10.1038/s41573-024-00979-4 ↗
30. Tumor microenvironmental pH and enzyme dual responsive polymer-liposomes for synergistic treatment of cancer immuno-chemotherapy10.1021/acs.biomac.8b01510 ↗
31. Outer membrane vesicle-wrapped manganese nanoreactor for augmenting cancer metalloimmunotherapy through hypoxia attenuation and immune stimulation10.1016/j.actbio.2024.05.010 ↗
32. Novel anti-pyroptosis drug loaded on metal-organic framework for intervertebral disc degeneration therapy
33. A pH-responsive hydrophilic controlled release system based on ZIF-8 for self-healing anticorrosion application10.1016/j.cej.2021.128985 ↗
34. In situ doxorubicin–CaP shell formation on amphiphilic gelatin–iron oxide core as a multifunctional drug delivery system with improved cytocompatibility, pH-responsive drug release and MR imaging10.1016/j.actbio.2012.09.023 ↗
35. Long-acting IL-2 release from pressure-fused biomineral tablets promotes antitumor immune response10.1038/s43018-025-00993-4 ↗
36. Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy
37. Review of potential health risks associated with nanoscopic calcium phosphate10.1016/j.actbio.2018.07.036 ↗
38. Arginine-loaded nano-calcium-phosphate-stabilized lipiodol pickering emulsions potentiates transarterial embolization-immunotherapy
39. Synergistic integration of experimental and simulation approaches for the de novo design of silk-based materials10.1021/acs.accounts.6b00616 ↗
40. Silk-elastin-like protein biomaterials for the controlled delivery of therapeutics10.1517/17425247.2015.989830 ↗
41. Hydrophobic drug-triggered self-assembly of nanoparticles from silk-elastin-like protein polymers for drug delivery10.1021/bm4017594 ↗
42. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis10.1002/ddr.22056 ↗
43. Tunable self-assembly of genetically engineered silk–elastin-like protein polymers10.1021/bm201165h ↗
44. Exploiting the dynamics of the EPR effect and strategies to improve the therapeutic effects of nanomedicines by using EPR effect enhancers10.1016/j.addr.2020.06.005 ↗
45. The EPR effect and beyond: strategies to improve tumor targeting and cancer nanomedicine treatment efficacy10.7150/thno.49577 ↗
46. Principles of nanoparticle design for overcoming biological barriers to drug delivery10.1038/nbt.3330 ↗
47. A polymer controlled nucleation route towards the generalized growth of organic-inorganic perovskite single crystals10.1038/s41467-021-22193-1 ↗
48. Advances in synthesis of calcium phosphate crystals with controlled size and shape10.1016/j.actbio.2014.06.017 ↗
49. X-ray photoelectron and ion scattering spectroscopic surface analyses of amorphous and crystalline calcium phosphate nanoparticles with different chemical histories10.1039/C9CP06529F ↗
50. Calcium signaling regulates autophagy and apoptosis10.3390/cells10082125 ↗
51. Regulation of autophagy by Ca(2)10.1007/s13277-016-5353-y ↗
52. Recent advances in calcium‐based anticancer nanomaterials exploiting calcium overload to trigger cell apoptosis
53. Connecting calcium-based nanomaterials and cancer: from diagnosis to therapy10.1007/s40820-022-00894-6 ↗
54. Biodegradable calcium phosphate nanotheranostics with tumor‐specific activatable cascade catalytic reactions‐augmented photodynamic therapy10.1002/adfm.202009848 ↗
55. GROMACS: a message-passing parallel molecular dynamics implementation10.1016/0010-4655(95)00042-E ↗
56. A Parrinello–Rahman approach to vortex lattices10.1016/j.physleta.2005.04.046 ↗
57. Particle mesh Ewald method for three-dimensional systems with two-dimensional periodicity10.1016/S0009-2614(01)00393-1 ↗